FGFR-targeted therapeutics for the treatment of breast cancer

Antonella De Luca, Daniela Frezzetti, Marianna Gallo, Nicola Normanno

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Breast cancer is a complex disease and several molecular drivers regulate its progression. Fibroblast growth factor receptor (FGFR) signaling is frequently deregulated in many cancers, including breast cancer. Due the involvement of the FGFR/FGF axis in the pathogenesis and progression of tumors, FGFR-targeted agents might represent a potential therapeutic option for breast cancer patients. Areas covered: This review offers an overview of targeted agents against FGFRs and their clinical development in breast cancer. The most relevant literature and the latest studies in the Clinicaltrial.com database have been discussed. Expert opinion: FGFR inhibition has been recently considered as a promising therapeutic option for different tumor types. However, preliminary results of clinical trials of FGFR inhibitors in breast cancer have been quite disappointing. In order to increase the clinical benefit of FGFR therapies in breast cancer, future studies should focus on: understanding the role of the various FGFR aberrations in cancer progression; identifying potential biomarkers to select patients that could benefit of FGFR inhibitors and developing therapeutic strategies that improve the efficacy of these agents and minimize toxicities.

Original languageEnglish
Pages (from-to)303-311
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number3
DOIs
Publication statusPublished - Mar 4 2017

Fingerprint

Fibroblast Growth Factor Receptors
Breast Neoplasms
Therapeutics
Neoplasms
Expert Testimony
Biomarkers
Clinical Trials
Databases

Keywords

  • breast cancer
  • FGFR genetic alterations
  • FGFR-targeted agents
  • Fibroblast growth factor receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

FGFR-targeted therapeutics for the treatment of breast cancer. / De Luca, Antonella; Frezzetti, Daniela; Gallo, Marianna; Normanno, Nicola.

In: Expert Opinion on Investigational Drugs, Vol. 26, No. 3, 04.03.2017, p. 303-311.

Research output: Contribution to journalReview article

@article{c242c5aa2bd645f989aa36592734a47f,
title = "FGFR-targeted therapeutics for the treatment of breast cancer",
abstract = "Introduction: Breast cancer is a complex disease and several molecular drivers regulate its progression. Fibroblast growth factor receptor (FGFR) signaling is frequently deregulated in many cancers, including breast cancer. Due the involvement of the FGFR/FGF axis in the pathogenesis and progression of tumors, FGFR-targeted agents might represent a potential therapeutic option for breast cancer patients. Areas covered: This review offers an overview of targeted agents against FGFRs and their clinical development in breast cancer. The most relevant literature and the latest studies in the Clinicaltrial.com database have been discussed. Expert opinion: FGFR inhibition has been recently considered as a promising therapeutic option for different tumor types. However, preliminary results of clinical trials of FGFR inhibitors in breast cancer have been quite disappointing. In order to increase the clinical benefit of FGFR therapies in breast cancer, future studies should focus on: understanding the role of the various FGFR aberrations in cancer progression; identifying potential biomarkers to select patients that could benefit of FGFR inhibitors and developing therapeutic strategies that improve the efficacy of these agents and minimize toxicities.",
keywords = "breast cancer, FGFR genetic alterations, FGFR-targeted agents, Fibroblast growth factor receptor",
author = "{De Luca}, Antonella and Daniela Frezzetti and Marianna Gallo and Nicola Normanno",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/13543784.2017.1287173",
language = "English",
volume = "26",
pages = "303--311",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - FGFR-targeted therapeutics for the treatment of breast cancer

AU - De Luca, Antonella

AU - Frezzetti, Daniela

AU - Gallo, Marianna

AU - Normanno, Nicola

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Breast cancer is a complex disease and several molecular drivers regulate its progression. Fibroblast growth factor receptor (FGFR) signaling is frequently deregulated in many cancers, including breast cancer. Due the involvement of the FGFR/FGF axis in the pathogenesis and progression of tumors, FGFR-targeted agents might represent a potential therapeutic option for breast cancer patients. Areas covered: This review offers an overview of targeted agents against FGFRs and their clinical development in breast cancer. The most relevant literature and the latest studies in the Clinicaltrial.com database have been discussed. Expert opinion: FGFR inhibition has been recently considered as a promising therapeutic option for different tumor types. However, preliminary results of clinical trials of FGFR inhibitors in breast cancer have been quite disappointing. In order to increase the clinical benefit of FGFR therapies in breast cancer, future studies should focus on: understanding the role of the various FGFR aberrations in cancer progression; identifying potential biomarkers to select patients that could benefit of FGFR inhibitors and developing therapeutic strategies that improve the efficacy of these agents and minimize toxicities.

AB - Introduction: Breast cancer is a complex disease and several molecular drivers regulate its progression. Fibroblast growth factor receptor (FGFR) signaling is frequently deregulated in many cancers, including breast cancer. Due the involvement of the FGFR/FGF axis in the pathogenesis and progression of tumors, FGFR-targeted agents might represent a potential therapeutic option for breast cancer patients. Areas covered: This review offers an overview of targeted agents against FGFRs and their clinical development in breast cancer. The most relevant literature and the latest studies in the Clinicaltrial.com database have been discussed. Expert opinion: FGFR inhibition has been recently considered as a promising therapeutic option for different tumor types. However, preliminary results of clinical trials of FGFR inhibitors in breast cancer have been quite disappointing. In order to increase the clinical benefit of FGFR therapies in breast cancer, future studies should focus on: understanding the role of the various FGFR aberrations in cancer progression; identifying potential biomarkers to select patients that could benefit of FGFR inhibitors and developing therapeutic strategies that improve the efficacy of these agents and minimize toxicities.

KW - breast cancer

KW - FGFR genetic alterations

KW - FGFR-targeted agents

KW - Fibroblast growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=85013293308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013293308&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1287173

DO - 10.1080/13543784.2017.1287173

M3 - Review article

C2 - 28121208

AN - SCOPUS:85013293308

VL - 26

SP - 303

EP - 311

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -